<https://rdf.molmedb.upol.cz/reference/ref3961> <http://purl.org/ontology/bibo/pmid> "21798738"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>;
	<http://purl.org/ontology/bibo/doi> "10.1016/j.bmcl.2011.06.129"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM492734>,
		<https://identifiers.org/molmedb/MM492677>;
	<http://purl.org/dc/terms/bibliographicCitation> "Zhang L, Fan J, Chong JH, Cesena A, Tam BY, Gilson C, Boykin C, Wang D, Aivazian D, Marcotte D, Xiao G, Le Brazidec JY, Piao J, Lundgren K, Hong K, Vu K, Nguyen K, Gan LS, Silvian L, Ling L, Teng M, Reff M, Takeda N, Timple N, Wang Q, Morena R, Khan S, Zhao S, Li T, Lee WC, Taveras AG, Chao J.: Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I). Bioorg Med Chem Lett, Volume 21 (18), 2011"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1029014> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3961> .
<https://rdf.molmedb.upol.cz/interaction/int1029103> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3961> .
